This is the protocol for a review and there is no abstract. The objectives are as follows: Primary To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9MABs on lipid parameters and CVD risk. Secondary To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.
ASJC Scopus subject areas
- Pharmacology (medical)